SMTI · CIK 714256
What Sanara MedTech Inc. told the SEC could break it.
Sanara MedTech's business leans heavily on one product and on partners it doesn't control. The substantial majority of its product revenue comes from a single product, CellerateRX Surgical — about $91.3 million of $103.1 million in total — so its fortunes track that one line. Beyond that, it licenses most of the products it sells from R&D partners, depending on them to classify products correctly and obtain FDA marketing authorizations, and it owns no manufacturing of its own, relying entirely on third-party manufacturing partners — so quality, capacity or compliance problems at those partners could disrupt its supply.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Supplier concentration
- reliance on R&D partners/licensors for most commercialized products and their FDA compliancemedium
Sanara licenses most of the products it commercializes from R&D partners and depends on those partners to determine FDA product classification and obtain proper marketing authorizations — so its product pipeline and regulatory compliance hinge on third parties it does not control.
“We rely on our research and development partners, from whom we license most of the products we currently commercialize, to determine the appropriate classification for each such product and to comply with applicable regulations related to obtaining the proper marketing authorization.”
SEC filing →As of 2026 - all manufacturing outsourced to third-party manufacturing partnersmedium
Sanara owns no manufacturing facilities and relies entirely on third-party manufacturing partners to produce its products, so quality, capacity or compliance problems at those partners could disrupt supply.
“Our manufacturing partners have internal compliance processes to maintain the high quality and reliability of our products.”
SEC filing →As of 2026
Other disclosures
- product concentration — substantial majority of revenue from CellerateRX Surgicalhigh
The substantial majority of Sanara's product-sales revenue comes from a single product, CellerateRX Surgical (soft-tissue repair was ~$91.3M of $103.1M total), concentrating its business in one product line.
“the substantial majority of our product sales revenue is derived from sales of CellerateRX Surgical.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings, including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its suppliers
Biomimetic Innovations Limited (BMI)
“On January 16, 2025, the Company entered into the BMI License Agreement, by and between the Company and BMI, a privately-held medical device company headquartered in Shannon, Co. Clare Ireland, pursuant to which the Company acquired the exclusive U.S. marketing, sales and distribution rights to OsStic Synthetic Injectable Structural Bio-Adhesive Bone Void Filler (“OsStic”)”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch